Literature DB >> 19296053

Interleukin-2 in CD8+ T cells correlates with Banff score during organ rejection in liver transplant recipients.

Bora Akoglu1, Susanne Kriener, Swantje Martens, Eva Herrmann, Wolf Peter Hofmann, Vladan Milovic, Stefan Zeuzem, Dominik Faust.   

Abstract

The aim of this study is to compare the histological grading of acute organ rejection according to the Banff score with intracellular interleukin-2 (IL-2) concentrations in cytotoxic CD8+ T cells from peripheral blood samples. 66 recipients after liver transplantation and 20 healthy controls were included into this study. Blood samples of liver transplant recipients were collected beside routine visits or, in case of suspected organ rejection, with additional liver biopsy. For cytometry, the blood cells were stained with CD3, CD8 and intracellular-IL-2. The percentage of cells with detectable intracellular IL-2 was significantly increased in patients with acute rejection (n = 7, P < 0.001, t Test) compared to recipients without rejection. The percentage of cells with detectable intracellular IL-2 (mean +/- SEM) was 7.6 +/- 0.9% in rejection patients, 2.3 +/- 0.22% in stable liver transplant recipients, and 14 +/- 2.99% in healthy controls. Intracellular IL-2 correlates to the Banff score in rejection patients (Spearmans-rho = 0.81, P < 0.05). This cytometric method shows a good sensitivity (71%) with a cut-off based on a high specificity of 95% for histological proven organ rejection in our study cohort. Measurement of intracellular IL-2 in cytotoxic CD8+ T-lymphocytes by flow cytometry correlates very well to the histological grading according to the Banff score and shows a good sensitivity and excellent specificity in acute organ rejection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19296053     DOI: 10.1007/s10238-009-0042-4

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  18 in total

1.  Reproducibility of the Banff classification in subclinical kidney transplant rejection.

Authors:  Francisco Veríssimo Veronese; Roberto Ceratti Manfro; Fernando Roberto Roman; Maria Isabel Edelweiss; David N Rush; Sylvia Dancea; Julio Goldberg; Luiz Felipe Gonçalves
Journal:  Clin Transplant       Date:  2005-08       Impact factor: 2.863

Review 2.  The mechanism of action of cyclosporin A and FK506.

Authors:  S Ho; N Clipstone; L Timmermann; J Northrop; I Graef; D Fiorentino; J Nourse; G R Crabtree
Journal:  Clin Immunol Immunopathol       Date:  1996-09

3.  Comparison of T cell responses in patients with a long-term surviving renal allograft versus a long-term surviving liver allograft. It's a different world.

Authors:  E van Twuyver; J de Hoop; R J ten Berge; J M Wilmink; S P Lems; A P van de Berg; M J Slooff; L P de Waal
Journal:  Transplantation       Date:  1996-05-15       Impact factor: 4.939

4.  Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial.

Authors:  J G O'Grady; A Burroughs; P Hardy; D Elbourne; A Truesdale
Journal:  Lancet       Date:  2002-10-12       Impact factor: 79.321

5.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes.

Authors:  J Liu; J D Farmer; W S Lane; J Friedman; I Weissman; S L Schreiber
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

6.  Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation.

Authors:  Martina Koch; Gerit Niemeyer; Indravadan Patel; Susan Light; Bjoern Nashan
Journal:  Transplantation       Date:  2002-05-27       Impact factor: 4.939

7.  Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection.

Authors:  Emmanuel Boleslawski; Filomena Conti; Sylvia Sanquer; Philippe Podevin; Sandrine Chouzenoux; Frédéric Batteux; Didier Houssin; Bernard Weill; Yvon Calmus
Journal:  Transplantation       Date:  2004-06-27       Impact factor: 4.939

8.  Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients.

Authors:  T D Batiuk; F Pazderka; P F Halloran
Journal:  Transplantation       Date:  1995-05-27       Impact factor: 4.939

9.  Enhanced risk of steroid-resistant acute rejection following pretransplant steroid therapy in liver graft recipients.

Authors:  F Conti; B Dousset; D Archambeau; A Louvel; D Houssin; Y Calmus
Journal:  Transplantation       Date:  1995-11-27       Impact factor: 4.939

10.  Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway.

Authors:  M J Dallman; O Shiho; T H Page; K J Wood; P J Morris
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Markers of acute rejection and graft acceptance in liver transplantation.

Authors:  Giacomo Germani; Kryssia Rodriguez-Castro; Francesco Paolo Russo; Marco Senzolo; Alberto Zanetto; Alberto Ferrarese; Patrizia Burra
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

Review 2.  Acute and Chronic Rejection After Liver Transplantation: What A Clinician Needs to Know.

Authors:  Narendra S Choudhary; Sanjiv Saigal; Rinkesh K Bansal; Neeraj Saraf; Dheeraj Gautam; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2017-11-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.